Richard Moriggl

List of Publications by Year
in descending order

228 papers	13,278 citations	18465 62 h-index	29127 104 g-index
244 all docs	244 docs citations	244 times ranked	17071 citing authors

#	Article	IF	Citations
1	Stat5 Is Required for IL-2-Induced Cell Cycle Progression of Peripheral T Cells. Immunity, 1999, 10, 249-259.	6.6	530
2	Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood, 2007, 109, 4368-4375.	0.6	488
3	Persistent STAT3 Activation in Colon Cancer Is Associated with Enhanced Cell Proliferation and Tumor Growth. Neoplasia, 2005, 7, 545-555.	2.3	344
4	Autocrine PDGFR signaling promotes mammary cancer metastasis. Journal of Clinical Investigation, 2006, 116, 1561-1570.	3.9	307
5	Deletion of the Carboxyl-Terminal Transactivation Domain of MGF-Stat5 Results in Sustained DNA Binding and a Dominant Negative Phenotype. Molecular and Cellular Biology, 1996, 16, 5691-5700.	1.1	262
6	A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis. Cancer Cell, 2013, 24, 167-181.	7.7	244
7	Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood, 2005, 105, 3303-3311.	0.6	226
8	Bone homeostasis in growth hormone receptorâ€“null mice is restored by IGF-I but independent of Stat5. Journal of Clinical Investigation, 2000, 106, 1095-1103.	3.9	225
9	Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. Journal of Clinical Investigation, 2007, 117, 1381-1390.	3.9	225
10	Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell, 2005, 7, 87-99.	7.7	213
11	Stat5 is indispensable for the maintenance of bcr/abl â€positive leukaemia. EMBO Molecular Medicine, 2010, 2, 98-110.	3.3	206
12	Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood, 2006, 107, 4898-4906.	0.6	192
13	Epidermal Growth Factor Receptor Signaling Synergizes with Hedgehog/GLI in Oncogenic Transformation via Activation of the MEK/ERK/JUN Pathway. Cancer Research, 2009, 69, 1284-1292.	0.4	189
14	JAK-STAT signaling in cancer: From cytokines to non-coding genome. Cytokine, 2016, 87, 26-36.	1.4	186
15	Stat5a/b contribute to interleukin 7â€“induced B-cell precursor expansion, but abl- andbcr/abl-induced transformation are independent of Stat5. Blood, 2000, 96, 2277-2283.	0.6	184
16	Cancer-associated fibroblast-derived WNT2 increases tumor angiogenesis in colon cancer. Angiogenesis, 2020, 23, 159-177.	3.7	174
17	High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood, 2011, 117, 3409-3420.	0.6	168
18	Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer. Leukemia, 2018, 32, 1713-1726.	3.3	166

#	Article	IF	Citations
19	Stat5 Activation Is Uniquely Associated with Cytokine Signaling in Peripheral T Cells. Immunity, 1999, 11, 225-230.	6.6	161
20	Advances in covalent kinase inhibitors. Chemical Society Reviews, 2020, 49, 2617-2687.	18.7	160
21	Specific DNA Binding of Stat5, but Not of Glucocorticoid Receptor, Is Required for Their Functional Cooperation in the Regulation of Gene Transcription. Molecular and Cellular Biology, 1997, 17, 6708-6716.	1.1	156
22	Antiapoptotic activity ofStat5required during terminal stages of myeloid differentiation. Genes and Development, 2000, 14, 232-244.	2.7	152
23	Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation. Genes and Development, 2000, 14, 232-44.	2.7	147
24	STAT1 acts as a tumor promoter for leukemia development. Cancer Cell, 2006, 10, 77-87.	7.7	136
25	STAT3 regulated ARF expression suppresses prostate cancer metastasis. Nature Communications, 2015, 6, 7736.	5.8	136
26	Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5. Blood, 2002, 99, 479-487.	0.6	134
27	Apoptosis Protection by the Epo Target Bcl-XL Allows Factor-Independent Differentiation of Primary Erythroblasts. Current Biology, 2002, 12, 1076-1085.	1.8	130
28	Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. Nature Communications, 2015, 6, 6285.	5.8	124
29	STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion. Cancer Discovery, 2016, 6, 414-429.	7.7	124
30	Comparison of the Transactivation Domains of Stat5 and Stat6 in Lymphoid Cells and Mammary Epithelial Cells. Molecular and Cellular Biology, 1997, 17, 3663-3678.	1.1	123
31	TYK2â€“STAT1â€“BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia. Cancer Discovery, 2013, 3, 564-577.	7.7	122
32	Signal Transducer and Activator of Transcription 3 Activation Promotes Invasive Growth of Colon Carcinomas through Matrix Metal loproteinase Induction. Neoplasia, 2007, 9, 279-291.	2.3	117
33	A small amphipathic alpha -helical region is required for transcriptional activities and proteasome-dependent turnover of the tyrosine-phosphorylated Stat5. EMBO Journal, 2000, 19, 392-399.	3.5	114
34	PDGFR blockade is a rational and effective therapy for NPM-ALKâ€“driven lymphomas. Nature Medicine, 2012, 18, 1699-1704.	15.2	113
35	Pharmacologic inhibition of STAT5 in acute myeloid leukemia. Leukemia, 2018, 32, 1135-1146.	3.3	112
36	Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia, 2015, 29, 586-597.	3.3	111

#	Article	IF	Citations
37	Glucocorticoid receptor function in hepatocytes is essential to promote postnatal body growth. Genes and Development, 2004, 18, 492-497.	2.7	110
38	Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. Blood, 2007, 109, 1678-1686.	0.6	108
39	Autocrine WNT2 signaling in fibroblasts promotes colorectal cancer progression. Oncogene, 2017, 36, 5460-5472.	2.6	107
40	Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2. Blood, 2008, 111, 4511-4522.	0.6	101
41	Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice. Hepatology, 2011, 54, 1398-1409.	3.6	100
42	Direct glucocorticoid receptor-Stat5 interaction in hepatocytes controls body size and maturation-related gene expression. Genes and Development, 2007, 21, 1157-1162.	2.7	99
43	Tumor target amplification: Implications for nano drug delivery systems. Journal of Controlled Release, 2018, 275, 142-161.	4.8	99
44	Afatinib restrains K-RASâ€“driven lung tumorigenesis. Science Translational Medicine, 2018, 10, .	5.8	99
45	IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon cancer through a paracrine tumorâ€“stroma interaction. Oncogene, 2015, 34, 815-825.	2.6	98
46	Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood, 2008, 112, 2463-2473.	0.6	97
47	Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma. British Journal of Cancer, 2013, 109, 138-146.	2.9	92
48	Stat5 Promotes Survival of Mammary Epithelial Cells through Transcriptional Activation of a Distinct Promoter in Akt1. Molecular and Cellular Biology, 2010, 30, 2957-2970.	1.1	90
49	The role of Stat5 transcription factors as tumor suppressors or oncogenes. Biochimica Et Biophysica Acta: Reviews on Cancer, 2011, 1815, 104-114.	3.3	90
50	Stat5 regulates cellular iron uptake of erythroid cells via IRP-2 and TfR-1. Blood, 2008, 112, 3878-3888.	0.6	87
51	The Interleukin-4 Receptor Activates STAT5 by a Mechanism That Relies upon Common Î³-Chain. Journal of Biological Chemistry, 1998, 273, 31222-31229.	1.6	77
52	Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5. Blood, 2000, 96, 2277-83.	0.6	77
53	A Single Amino Acid in the DNA Binding Regions of STAT5A and STAT5B Confers Distinct DNA Binding Specificities. Journal of Biological Chemistry, 1998, 273, 33936-33941.	1.6	76
54	JunB inhibits proliferation and transformation in B-lymphoid cells. Blood, 2003, 102, 4159-4165.	0.6	76

#	Article	IF	Citations
55	Activated STAT5 Confers Resistance to Intestinal Injury by Increasing Intestinal Stem Cell Proliferation and Regeneration. Stem Cell Reports, 2015, 4, 209-225.	2.3	76
56	Unique Effects of KIT D816V in BaF3 Cells: Induction of Cluster Formation, Histamine Synthesis, and Early Mast Cell Differentiation Antigens. Journal of Immunology, 2008, 180, 5466-5476.	0.4	75
57	Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL. Nature Communications, 2018, 9, 697.	5.8	73
58	Expression of Activated STAT5 in Neoplastic Mast Cells in Systemic Mastocytosis. American Journal of Pathology, 2009, 175, 2416-2429.	1.9	72
59	Type I Interferon Signaling Disrupts the Hepatic Urea Cycle and Alters Systemic Metabolism to Suppress T Cell Function. Immunity, 2019, 51, 1074-1087.e9.	6.6	72
60	Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model. Oncotarget, 2017, 8, 34141-34163.	0.8	72
61	Homodimerization of Interleukin-4 Receptor Î± Chain Can Induce Intracellular Signaling. Journal of Biological Chemistry, 1996, 271, 23634-23637.	1.6	67
62	Induction of 3Î²-Hydroxysteroid Dehydrogenase/Î”5-Î”4 Isomerase Type 1 Gene Transcription in Human Breast Cancer Cell Lines and in Normal Mammary Epithelial Cells by Interleukin-4 and Interleukin-13. Molecular Endocrinology, 1999, 13, 66-81.	3.7	67
63	Hepatic growth hormone and glucocorticoid receptor signaling in body growth, steatosis and metabolic liver cancer development. Molecular and Cellular Endocrinology, 2012, 361, 1-11.	1.6	65
64	Direct Targeting Options for STAT3 and STAT5 in Cancer. Cancers, 2019, 11, 1930.	1.7	65
65	STAT5 triggersBCR-ABL1mutation by mediating ROS production in chronic myeloid leukaemia. Oncotarget, 2012, 3, 1669-1687.	0.8	64
66	Enterocyte STAT5 promotes mucosal wound healing via suppression of myosin light chain kinaseâ€mediated loss of barrier function and inflammation. EMBO Molecular Medicine, 2012, 4, 109-124.	3.3	64
67	STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease. Blood, 2010, 115, 1416-1424.	0.6	63
68	Prolactin and interleukin-2 receptors in T lymphocytes signal through a MGF-STAT5-like transcription factor.. Endocrinology, 1995, 136, 5700-5708.	1.4	62
69	Epigenetic program and transcription factor circuitry of dendritic cell development. Nucleic Acids Research, 2015, 43, gkv1056.	6.5	62
70	Ischemic brain injury: A consortium analysis of key factors involved in mesenchymal stem cell-mediated inflammatory reduction. Archives of Biochemistry and Biophysics, 2013, 534, 88-97.	1.4	60
71	First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. Blood, 2017, 130, 2499-2503.	0.6	59
72	Dominant Negative Variants of the SHP-2 Tyrosine Phosphatase Inhibit Prolactin Activation of Jak2 (Janus Kinase 2) and Induction of Stat5 (Signal Transducer and Activator of Transcription 5)-Dependent Transcription. Molecular Endocrinology, 1998, 12, 556-567.	3.7	58

#	Article	IF	Citations
73	Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 20423-20428.	3.3	58
74	Promising New Sources for Pluripotent Stem Cells. Stem Cell Reviews and Reports, 2010, 6, 15-26.	5.6	58
75	STAT5BN642H is a driver mutation for T cell neoplasia. Journal of Clinical Investigation, 2017, 128, 387-401.	3.9	57
76	Erythroid progenitor renewal versus differentiation: genetic evidence for cell autonomous, essential functions of EpoR, Stat5 and the GR. Oncogene, 2006, 25, 2890-2900.	2.6	56
77	Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation. Blood, 2010, 116, 1548-1558.	0.6	56
78	PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis. Leukemia, 2014, 28, 629-641.	3.3	56
79	The second European interdisciplinary Ewing sarcoma research summit - A joint effort to deconstructing the multiple layers of a complex disease. Oncotarget, 2016, 7, 8613-8624.	0.8	55
80	NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells. Leukemia, 2016, 30, 473-483.	3.3	54
81	JAKâ€“STAT inhibition impairs Kâ€RASâ€driven lung adenocarcinoma progression. International Journal of Cancer, 2019, 145, 3376-3388.	2.3	54
82	Crosstalk between inflammatory mediators and endoplasmic reticulum stress in liver diseases. Cytokine, 2019, 124, 154577.	1.4	54
83	Adipocyte Glucocorticoid Receptor Deficiency Attenuates Aging- and HFD-Induced Obesity and Impairs the Feeding-Fasting Transition. Diabetes, 2017, 66, 272-286.	0.3	53
84	Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy. Haematologica, 2014, 99, 417-429.	1.7	50
85	Structural and functional consequences of the STAT5BN642H driver mutation. Nature Communications, 2019, 10, 2517.	5.8	50
86	Oncogenic role of <scp>miR</scp>â€155 in anaplastic large cell lymphoma lacking the t(2;5) translocation. Journal of Pathology, 2015, 236, 445-456.	2.1	49
87	Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts. Haematologica, 2018, 103, 1593-1603.	1.7	49
88	Disruption of the growth hormone-Signal transducer and activator of transcription 5-Insulinlike growth factor 1 axis severely aggravates liver fibrosis in a mouse model of cholestasis. Hepatology, 2010, 51, 1319-1326.	3.6	48
89	Adipocyte STAT5 deficiency promotes adiposity and impairs lipid mobilisation in mice. Diabetologia, 2017, 60, 296-305.	2.9	48
90	p19ARF/p14ARF controls oncogenic functions of signal transducer and activator of transcription 3 in hepatocellular carcinoma. Hepatology, 2011, 54, 164-172.	3.6	47

#	Article	IF	Citations
91	O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies. Leukemia, 2017, 31, 2132-2142.	3.3	47
92	When the guardian sleeps: Reactivation of the p53 pathway in cancer. Mutation Research - Reviews in Mutation Research, 2017, 773, 1-13.	2.4	47
93	Hepatic growth hormone - JAK2 - STAT5 signalling: Metabolic function, non-alcoholic fatty liver disease and hepatocellular carcinoma progression. Cytokine, 2019, 124, 154569.	1.4	47
94	Induction of 3Â-Hydroxysteroid Dehydrogenase/Â5-Â4 Isomerase Type 1 Gene Transcription in Human Breast Cancer Cell Lines and in Normal Mammary Epithelial Cells by Interleukin-4 and Interleukin-13. Molecular Endocrinology, 1999, 13, 66-81.	3.7	47
95	CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia. Blood, 2020, 136, 387-400.	0.6	46
96	Structural Implications of STAT3 and STAT5 SH2 Domain Mutations. Cancers, 2019, 11, 1757.	1.7	45
97	The dark and the bright side of Stat3: proto-oncogene and tumor-suppressor. Frontiers in Bioscience - Landmark, 2009, Volume, 2944.	3.0	44
98	The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease. Cancer Cell, 2019, 35, 125-139.e9.	7.7	43
99	Growth-hormoneâ€“induced signal transducer and activator of transcription 5 signaling causes gigantism, inflammation, and premature death but protects mice from aggressive liver cancer. Hepatology, 2012, 55, 941-952.	3.6	42
100	STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pathway. Oncogene, 2021, 40, 1091-1105.	2.6	42
101	STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease. Kidney International, 2017, 91, 575-586.	2.6	41
102	Stat5a/b contribute to interleukin 7â€“induced B-cell precursor expansion, but abl- andbcr/abl-induced transformation are independent of Stat5. Blood, 2000, 96, 2277-2283.	0.6	41
103	Gadd45Î³ Is Dispensable for Normal Mouse Development and T-Cell Proliferation. Molecular and Cellular Biology, 2001, 21, 3137-3143.	1.1	40
104	Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. Leukemia, 2019, 33, 696-709.	3.3	40
105	Activation of STAT5 by IL-4 relies on Janus kinase function but not on receptor tyrosine phosphorylation, and can contribute to both cell proliferation and gene regulation. International Immunology, 1999, 11, 1283-1294.	1.8	39
106	The different functions of Stat5 and chromatin alteration through Stat5 proteins. Frontiers in Bioscience - Landmark, 2008, Volume, 6237.	3.0	39
107	Inhibition of STAT5: A therapeutic option in BCR-ABL1-driven leukemia. Oncotarget, 2014, 5, 9564-9576.	0.8	39
108	STAT5 requires the N-domain to maintain hematopoietic stem cell repopulating function and appropriate lymphoid-myeloid lineage output. Experimental Hematology, 2007, 35, 1684-1694.	0.2	37

#	Article	IF	Citations
109	STAT3 controls matrix metalloproteinase-1 expression in colon carcinoma cells by both direct and AP-1-mediated interaction with the MMP-1 promoter. Biological Chemistry, 2011, 392, 449-59.	1.2	37
110	NGR (Asn-Gly-Arg)-targeted delivery of coagulase to tumor vasculature arrests cancer cell growth. Oncogene, 2018, 37, 3967-3980.	2.6	37
111	Cytokine Receptor-independent, Constitutively Active Variants of STAT5. Journal of Biological Chemistry, 1997, 272, 30237-30243.	1.6	36
112	Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia. Haematologica, 2017, 102, 1519-1529.	1.7	36
113	New perspectives in stem cell research: beyond embryonic stem cells. Cell Proliferation, 2011, 44, 9-14.	2.4	35
114	AF1q is a novel TCF7 co-factor which activates CD44 and promotes breast cancer metastasis. Oncotarget, 2015, 6, 20697-20710.	0.8	35
115	Persistent STAT5 activation in myeloid neoplasms recruits p53 into gene regulation. Oncogene, 2015, 34, 1323-1332.	2.6	34
116	The ratio of STAT1 to STAT3 expression is a determinant of colorectal cancer growth. Oncotarget, 2016, 7, 51096-51106.	0.8	34
117	MLLT11/AF1q boosts oncogenic STAT3 activity through Src-PDGFR tyrosine kinase signaling. Oncotarget, 2016, 7, 43960-43973.	0.8	34
118	Jak1 deficiency leads to enhanced Abelson-induced B-cell tumor formation. Blood, 2003, 101, 4937-4943.	0.6	33
119	Natural compound methyl protodioscin protects against intestinal inflammation through modulation of intestinal immune responses. Pharmacology Research and Perspectives, 2015, 3, e00118.	1.1	33
120	Oncogenic STAT5 signaling promotes oxidative stress in chronic myeloid leukemia cells by repressing antioxidant defenses. Oncotarget, 2017, 8, 41876-41889.	0.8	33
121	The First European Interdisciplinary Ewing Sarcoma Research Summit. Frontiers in Oncology, 2012, 2, 54.	1.3	32
122	JAKâ€STAT core cancer pathway: An integrative cancer interactome analysis. Journal of Cellular and Molecular Medicine, 2022, 26, 2049-2062.	1.6	32
123	Reliable Quantification of Protein Expression and Cellular Localization in Histological Sections. PLoS ONE, 2014, 9, e100822.	1.1	31
124	A novel germline JAK2 mutation in familial myeloproliferative neoplasms. American Journal of Hematology, 2014, 89, 117-118.	2.0	31
125	Lung Adenocarcinomas and Lung Cancer Cell Lines Show Association of MMP-1 Expression With STAT3 Activation. Translational Oncology, 2015, 8, 97-105.	1.7	31
126	SIAH2 antagonizes TYK2-STAT3 signaling in lung carcinoma cells. Oncotarget, 2014, 5, 3184-3196.	0.8	31

#	Article	IF	Citations
127	Src family kinases mediate cytoplasmic retention of activated STAT5 in BCRâ€“ABL-positive cells. Oncogene, 2013, 32, 3587-3597.	2.6	30
128	High Keratin 8/18 Ratio Predicts Aggressive Hepatocellular Cancer Phenotype. Translational Oncology, 2019, 12, 256-268.	1.7	28
129	Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia. Journal of Medicinal Chemistry, 2021, 64, 8486-8509.	2.9	28
130	A rare castrationâ€resistant progenitor cell population is highly enriched in Ptenâ€null prostate tumours. Journal of Pathology, 2017, 243, 51-64.	2.1	27
131	Steering of carcinoma progression by the YIN/YANG interaction of STAT1/STAT3. BioScience Trends, 2017, 11, 1-8.	1.1	27
132	High activation of STAT5A drives peripheral T-cell lymphoma and leukemia. Haematologica, 2020, 105, 435-447.	1.7	27
133	Regulation of the trans-activation potential of STAT5 through its DNA-binding activity and interactions with heterologous transcription factors. Growth Hormone and IGF Research, 2000, 10, S15-S20.	0.5	26
134	Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with rapamycin. Leukemia, 2010, 24, 1397-1405.	3.3	26
135	Opioids drive breast cancer metastasis through the Î´-opioid receptor and oncogenic STAT3. Neoplasia, 2021, 23, 270-279.	2.3	26
136	Presence or absence of TGF-beta determines IL-4-induced generation of type 1 or type 2 CD8 T cell subsets. Journal of Immunology, 1999, 162, 209-14.	0.4	26
137	Human stem cells alter the invasive properties of somatic cells via paracrine activation of mTORC1. Nature Communications, 2017, 8, 595.	5.8	25
138	A role for STAT5A/B in protection of peripheral T-lymphocytes from postactivation apoptosis: Insights from gene expression profiling. Cytokine, 2006, 34, 143-154.	1.4	24
139	Hepatic Deletion of Janus Kinase 2 Counteracts Oxidative Stress in Mice. Scientific Reports, 2016, 6, 34719.	1.6	24
140	A hydride transfer complex reprograms NAD metabolism and bypasses senescence. Molecular Cell, 2021, 81, 3848-3865.e19.	4.5	24
141	YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model. Oncotarget, 2015, 6, 37678-37694.	0.8	24
142	Synergistic crossâ€talk of hedgehog and interleukinâ€6 signaling drives growth of basal cell carcinoma. International Journal of Cancer, 2018, 143, 2943-2954.	2.3	23
143	A STAT5Bâ€“CD9 axis determines self-renewal in hematopoietic and leukemic stem cells. Blood, 2021, 138, 2347-2359.	0.6	23
144	Diverging fates of cells of origin in acute and chronic leukaemia. EMBO Molecular Medicine, 2012, 4, 283-297.	3.3	22

#	Article	IF	Citations
145	The unfolded protein response impacts melanoma progression by enhancing FGF expression and can be antagonized by a chemical chaperone. Scientific Reports, 2017, 7, 17498.	1.6	22
146	Malignant Phenotypes in Metastatic Melanoma are Governed by SR-BI and its Association with Glycosylation and STAT5 Activation. Molecular Cancer Research, 2018, 16, 135-146.	1.5	21
147	Activation of STAT proteins and cytokine genes in human Th1 and Th2 cells generated in the absence of IL-12 and IL-4. Journal of Immunology, 1998, 160, 3385-92.	0.4	21
148	Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells. Leukemia, 2018, 32, 1016-1022.	3.3	20
149	STAT3 activation in large granular lymphocyte leukemia is associated with cytokine signaling and DNA hypermethylation. Leukemia, 2021, 35, 3430-3443.	3.3	20
150	STAT3Î² is a tumor suppressor in acute myeloid leukemia. Blood Advances, 2019, 3, 1989-2002.	2.5	20
151	Constitutive STAT5 activation regulates Paneth and Paneth-like cells to control Clostridium difficile colitis. Life Science Alliance, 2019, 2, e201900296.	1.3	20
152	The <scp>JAK2</scp>/<scp>STAT5</scp> signaling pathway as a potential therapeutic target in canine mastocytoma. Veterinary and Comparative Oncology, 2018, 16, 55-68.	0.8	19
153	Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas. Expert Opinion on Therapeutic Targets, 2018, 22, 45-57.	1.5	19
154	The Inhibition of Stat5 by a Peptide Aptamer Ligand Specific for the DNA Binding Domain Prevents Target Gene Transactivation and the Growth of Breast and Prostate Tumor Cells. Pharmaceuticals, 2013, 6, 960-987.	1.7	18
155	The neonatal microenvironment programs innate Î³Î´ T cells through the transcription factor STAT5. Journal of Clinical Investigation, 2020, 130, 2496-2508.	3.9	18
156	Stat5 Exerts Distinct, Vital Functions in the Cytoplasm and Nucleus of Bcr-Abl+ K562 and Jak2(V617F)+ HEL Leukemia Cells. Cancers, 2015, 7, 503-537.	1.7	17
157	Noncanonical effector functions of the T-memoryâ€“like T-PLL cell are shaped by cooperative TCL1A and TCR signaling. Blood, 2020, 136, 2786-2802.	0.6	17
158	Thyroid and androgen receptor signaling are antagonized by Î¼â€Crystallin in prostate cancer. International Journal of Cancer, 2021, 148, 731-747.	2.3	17
159	Interleukinâ€6 receptor alpha blockade improves skin lesions in a murine model of systemic lupus erythematosus. Experimental Dermatology, 2016, 25, 305-310.	1.4	16
160	TYK2 licenses non-canonical inflammasome activation during endotoxemia. Cell Death and Differentiation, 2021, 28, 748-763.	5.0	16
161	Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal. Frontiers in Veterinary Science, 2021, 8, 755258.	0.9	16
162	A mouse model to identify cooperating signaling pathways in cancer. Nature Methods, 2012, 9, 897-900.	9.0	15

#	Article	IF	Citations
163	STAT5 is required for lipid breakdown and beta-adrenergic responsiveness of brown adipose tissue. Molecular Metabolism, 2020, 40, 101026.	3.0	15
164	Activation of STAT6 is not dependent on phosphotyrosine-mediated docking to the interleukin-4 receptor and can be blocked by dominant-negative mutants of both receptor subunits. FEBS Journal, 1998, 251, 25-35.	0.2	14
165	Sensitized phenotypic screening identifies gene dosage sensitive region on chromosome 11 that predisposes to disease in mice. EMBO Molecular Medicine, 2011, 3, 50-66.	3.3	14
166	STAT5 deficiency in hepatocytes reduces diethylnitrosamine-induced liver tumorigenesis in mice. Cytokine, 2019, 124, 154573.	1.4	14
167	<scp>AKT</scp>3 drives adenoid cystic carcinoma development in salivary glands. Cancer Medicine, 2018, 7, 445-453.	1.3	13
168	The stromal microenvironment provides an escape route from FLT3 inhibitors through the GAS6-AXL-STAT5 axis. Haematologica, 2019, 104, 1907-1909.	1.7	13
169	The Diverse Roles of Î³Î´ T Cells in Cancer: From Rapid Immunity to Aggressive Lymphoma. Cancers, 2021, 13, 6212.	1.7	13
170	Acetylation and sumoylation control STAT5 activation antagonistically. Jak-stat, 2012, 1, 203-207.	2.2	12
171	STAT5a/b Deficiency Delays, but does not Prevent, Prolactin-Driven Prostate Tumorigenesis in Mice. Cancers, 2019, 11, 929.	1.7	12
172	Cell Metabolism Control Through O-GlcNAcylation of STAT5: A Full or Empty Fuel Tank Makes a Big Difference for Cancer Cell Growth and Survival. International Journal of Molecular Sciences, 2019, 20, 1028.	1.8	12
173	STAT5BN642H drives transformation of NKT cells: a novel mouse model for CD56+ T-LGL leukemia. Leukemia, 2019, 33, 2336-2340.	3.3	12
174	STAT5 is Expressed in CD34+/CD38â^' Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms. Cancers, 2020, 12, 1021.	1.7	12
175	A centric view of JAK/STAT5 in intestinal homeostasis, infection, and inflammation. Cytokine, 2021, 139, 155392.	1.4	12
176	Expansion of <scp>BCR</scp>/<scp>ABL</scp>1⁺ cells requires <scp>PAK</scp>2 but not <scp>PAK</scp>1. British Journal of Haematology, 2017, 179, 229-241.	1.2	11
177	Pharmacologic IL-6RÎ± inhibition in cholangiocarcinoma promotes cancer cell growth and survival. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 308-321.	1.8	11
178	Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions. HemaSphere, 2021, 5, e536.	1.2	11
179	Serine phosphorylation of the Stat5a C-terminus is a driving force for transformation. Frontiers in Bioscience - Landmark, 2011, 16, 3043.	3.0	10
180	Down-regulation of A20 promotes immune escape of lung adenocarcinomas. Science Translational Medicine, 2021, 13, .	5.8	10

#	Article	IF	Citations
181	Stat5 gene dosage in T cells modulates CD8+T-cell homeostasis and attenuates contact hypersensitivity response in mice. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 67-79.	2.7	9
182	Life Under Hypoxia Lowers Blood Glucose Independently of Effects on Appetite and Body Weight in Mice. Frontiers in Endocrinology, 2018, 9, 490.	1.5	7
183	Targeting STAT3 and STAT5 in Cancer. Cancers, 2020, 12, 2002.	1.7	7
184	Proteomic Analysis Identifies NDUFS1 and ATP5O as Novel Markers for Survival Outcome in Prostate Cancer. Cancers, 2021, 13, 6036.	1.7	7
185	STAT5A/5B-specific expansion and transformation of hematopoietic stem cells. Blood Cancer Journal, 2017, 7, e514-e514.	2.8	6
186	Cooperation of ETV6/RUNX1 and BCL2 enhances immunoglobulin production and accelerates glomerulonephritis in transgenic mice. Oncotarget, 2016, 7, 12191-12205.	0.8	6
187	Variants in STAT5B Associate with Serum TC and LDL-C Levels. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1496-E1501.	1.8	5
188	Oncogenic Kinase Cascades Induce Molecular Mechanisms That Protect Leukemic Cell Models from Lethal Effects of De Novo dNTP Synthesis Inhibition. Cancers, 2021, 13, 3464.	1.7	5
189	A Detailed Protocol for Bacterial Artificial Chromosome Recombineering to Study Essential Genes in Stem Cells. Methods in Molecular Biology, 2008, 430, 269-293.	0.4	4
190	A Recurrent STAT5BN642H Driver Mutation in Feline Alimentary T Cell Lymphoma. Cancers, 2021, 13, 5238.	1.7	4
191	A haunted beast: Targeting STAT5BN642H in T-Cell Neoplasia. Molecular and Cellular Oncology, 2018, 5, e1435181.	0.3	3
192	Differential Roles of Cytokine Signaling during T-cell Development. Cold Spring Harbor Symposia on Quantitative Biology, 1999, 64, 389-396.	2.0	3
193	Structural and utational nalysis of ember-pecific STAT unctions. Biochimica Et Biophysica Acta - General Subjects, 2022, 1866, 130058.	1.1	3
194	The antiapoptotic function of megakaryocyte growth and development factor (Peg-rmMGDF) Is disrupted in STAT5ab â˜’ /â˜’ and JAK2 + /â˜’ mice. Experimental Hematology, 2000, 28, 51.	0.2	2
195	Declined presentation. Experimental Hematology, 2013, 41, S48.	0.2	2
196	Editorial: Recovery from chemotherapy depends on STAT1 for replenishment of B lymphopoiesis. Journal of Leukocyte Biology, 2014, 95, 849-851.	1.5	2
197	Interplay of transcription factors STAT3, STAT1 and AP-1 mediates activity of the matrix metallo-proteinase-1 promoter in colorectal carcinoma cells. Neoplasma, 2019, 66, 357-366.	0.7	2
198	STAT3 Inhibition Synergizes with BCR-ABL1 Inhibition to Overcome Kinase-Independent TKI Resistance in Chronic Myeloid Leukemia (CML). Blood, 2012, 120, 31-31.	0.6	2

#	Article	IF	Citations
199	Adipocyte STAT5 deficiency does not affect blood glucose homeostasis in obese mice. PLoS ONE, 2021, 16, e0260501.	1.1	2
200	Stat5 as a Hematopoietic Master Regulator for Differentiation and Neoplasia Development. , 2012, , 153-167.		1
201	Editorial: Cytokines in liver diseases. Cytokine, 2019, 124, 154608.	1.4	1
202	Endogenous N-Terminal Truncated STAT5 Expressed from Alternative Start Codons Promotes SCF Signaling in Murine Primary Mast Cell Cultures.. Blood, 2004, 104, 815-815.	0.6	1
203	TYK2-STAT1 Pathway Positively Regulates BCL2 Gene Expression in T-Cell Acute Lymphoblastic Leukemia. Blood, 2012, 120, 1470-1470.	0.6	1
204	Oncogenic TYK2^{P760L} kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade. Haematologica, 2022, , .	1.7	1
205	Efficacy and Synergy of Small Molecule Inhibitors Targeting FLT3-ITD+ Acute Myeloid Leukemia. Cancers, 2021, 13, 6181.	1.7	1
206	Correlation of malignancy parameters in colorectal carcinoma with up- and downstream signalling partners of STAT3. Cell Communication and Signaling, 2009, 7, .	2.7	0
207	895 A PRO- AND ANTI-ONCOGENIC ROLE OF STAT3 IN HEPATOCELLULAR CARCINOMA PROGRESSION. Journal of Hepatology, 2010, 52, S348.	1.8	0
208	7018 POSTER NFkB Activity Modulates the Oncogenic Potential of Stat3 in Prostate Cancer Development. European Journal of Cancer, 2011, 47, S490.	1.3	0
209	Enterocyte STAT5 promotes mucosal wound healing via suppression of myosin light chain kinase-mediated loss of barrier function and inflammation. Inflammatory Bowel Diseases, 2011, 17, S81.	0.9	0
210	STAT5 - a central player in BCR/ABL+ leukemia. Experimental Hematology, 2013, 41, S6.	0.2	0
211	Reply. Hepatology, 2013, 58, 2210-2210.	3.6	0
212	ID: 263. Cytokine, 2015, 76, 112.	1.4	0
213	ID: 66. Cytokine, 2015, 76, 77.	1.4	0
214	32 Cytokine-STAT5 Signaling Controls Intestinal Stem Cell Activation to Suppress Clostridium Difficile - Induced Gut Inflammation. Gastroenterology, 2016, 150, S11.	0.6	0
215	Cover Image, Volume 16, Issue 1. Veterinary and Comparative Oncology, 2018, 16, i.	0.8	0
216	Detection of Activated STAT5 in the Cytoplasm of Neoplastic Cells in Patients with AML, CML, and Systemic Mastocytosis.. Blood, 2006, 108, 2305-2305.	0.6	0

#	Article	IF	Citations
217	Pathway Dependence on the Tyrosine Kinase TYK2 and Its Mediator STAT1 In T-Cell Acute Lymphoblastic Leukemia. Blood, 2010, 116, 3155-3155.	0.6	0
218	Abstract 2809: Pathway dependence on the tyrosine kinase TYK2 in T-cell acute lymphoblastic leukemia. , 2011, , .		0
219	Abstract 4880: Disruption of STAT3 signaling promotes K-Ras induced lung tumorigenesis. , 2012, , .		0
220	BP5-087, a Novel STAT3 Inhibitor, Combines With BCR-ABL1 Inhibition To Overcome Kinase-Independent Resistance In Chronic Myeloid Leukemia. Blood, 2013, 122, 854-854.	0.6	0
221	Abstract 79: Deletion of STAT3 in a mouse model for metastatic melanoma. , 2014, , .		0
222	Abstract 61: A mouse model for small round cell tumors induced by the Ewing sarcoma oncogene EWS/FLI1. , 2014, , .		0
223	Abstract 108: Consequences of hepatic JAK2 deficiency for liver metabolism and hepatocarcinogenesis. , 2014, , .		0
224	Abstract 3138: IL-6/Stat3 signaling is an indispensable modulator of oncogene-induced cellular senescence. , 2014, , .		0
225	Abstract 3284: Unfavorable outcomes of EWS-FLI1 expression in different tissues of a transgenic mouse model. , 2015, , .		0
226	Abstract 1184: Characterization of novel STAT5 inhibitors to interfere with the oncogenic activities of STAT5 in hematopoietic diseases. , 2017, , .		0
227	Abstract 4463: The coactivator oncogene AF1Q associates with STAT3 activation downstream of MET action in gastro-esophageal cancer patients. , 2017, , .		0
228	P097 REGULATION OF PANETH CELL LINEAGES FOR REGIONAL IMMUNE SPECIALIZATION TO CONTROL COMORBIDITY OF C. DIFFICILE INFECTION WITH IBD. Gastroenterology, 2018, 154, S50.	0.6	0